CN111999404A - 神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用 - Google Patents
神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用 Download PDFInfo
- Publication number
- CN111999404A CN111999404A CN202010819852.9A CN202010819852A CN111999404A CN 111999404 A CN111999404 A CN 111999404A CN 202010819852 A CN202010819852 A CN 202010819852A CN 111999404 A CN111999404 A CN 111999404A
- Authority
- CN
- China
- Prior art keywords
- thyroid
- malignant tumor
- nervonic acid
- detection reagent
- biomarker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 title claims abstract description 32
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 title claims abstract description 31
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 210000001685 thyroid gland Anatomy 0.000 title claims abstract description 29
- 201000011510 cancer Diseases 0.000 title claims abstract description 27
- 238000001514 detection method Methods 0.000 title claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 17
- 239000000090 biomarker Substances 0.000 claims abstract description 14
- TXFLWJQVQCDUDZ-BRUGZULGSA-N N-(15Z-tetracosenoyl)-4E,14Z-sphingadienine-1-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCC\C=C/CCC TXFLWJQVQCDUDZ-BRUGZULGSA-N 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 230000036210 malignancy Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 abstract description 11
- 230000003211 malignant effect Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000009453 Thyroid Nodule Diseases 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 239000002207 metabolite Substances 0.000 abstract description 4
- 238000003759 clinical diagnosis Methods 0.000 abstract description 3
- 239000003550 marker Substances 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 description 11
- 208000024770 Thyroid neoplasm Diseases 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010054107 Nodule Diseases 0.000 description 3
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 102000000802 Galectin 3 Human genes 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 238000011353 adjuvant radiotherapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000016842 benign thyroid gland neoplasm Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用,它涉及药物试剂领域。应用:制备甲状腺恶性肿瘤的检测试剂以神经酸SM(d18:2/24:1)作为甲状腺恶性肿瘤的生物标记物。本发明提供了一种无创的、有效的、可靠的血清标志物来鉴别良、恶性甲状腺结节,避免了侵入性手术对患者身心的影响,同时提高了检测速度及准确率。本发明以神经酸SM(d18:2/24:1)作为甲状腺恶性肿瘤的生物标记物,其代谢组的检测通过血液就可以进行,其次代谢组学可以检测到小分子代谢物,可以很好地阐述甲状腺恶性肿瘤可能发生的变化,最后通过神经酸的发现,可很好地指导临床上对疾病的诊疗情况的掌握。本发明适用于作为甲状腺恶性肿瘤的生物标记物。
Description
技术领域
本发明涉及药物试剂领域,具体涉及神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用。
背景技术
甲状腺癌是头颈部恶性肿瘤中最常见的内分泌恶性肿瘤,它占所有内分泌恶性肿瘤的91.5%,占所有恶性疾病的1%,并且呈逐年上升趋势。早期准确诊断和及时治疗是提高PTC(乳头状甲状腺癌)患者长期生存率的关键。甲状腺癌的诊断工具很多,如超声、计算机断层扫描、磁共振成像、细胞学检查和细针抽吸等。目前超声引导细针穿刺活检被认为是鉴别甲状腺良恶性结节最有效的检查方法,但这是一种侵入性手术。因此,寻找新的无创、有效、可靠的血清标志物来鉴别良、恶性甲状腺结节,对于甲状腺癌的诊断是必要的。
近年来研究者们一直在寻找有价值的甲状腺癌诊断的生物标志物,如:galectin-3,fibronectin-1,CITED-1,HBME1,cytokeratin-19andTPO等。令人失望的是,所有这些生物标记物要么在某种程度上缺乏特异性,要么具有较差的阳性预测值。为了更准确地鉴别甲状腺恶性结节和良性病变,诊断试验仍需改进。
由于代谢在癌症中的重要作用,脂质作为生物标记物的应用受到了进一步的推动。脂质代谢的破坏通过相关的信号通路发挥作用,改变了细胞的功能,导致癌变及其进展。对于甲状腺癌,代谢组学显示出对癌症诊断的潜力。有报导,磷脂,包括磷脂酰胆碱(PCs),磷脂酸(PAs)和鞘磷脂酰肌醇(SMs)在甲状腺良、恶性肿瘤与正常人的组织和血清中含量不同。如果找到甲状腺癌患者独特的血清脂质谱,就有可能成为甲状腺癌早期诊断的新生物标志物。
发明内容
本发明目的是提供神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用。
神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用:所述检测试剂以神经酸SM(d18:2/24:1)作为甲状腺恶性肿瘤的生物标记物。
本发明发现了神经酸SM(d18:2/24:1)新的应用领域,将进一步扩大其药用范围及市场需求。同时本发明将神经酸SM(d18:2/24:1)应用到制备甲状腺恶性肿瘤的检测试剂中,提供了一种无创的、有效的、可靠的血清标志物来鉴别良、恶性甲状腺结节,它将取代目前超声引导细针穿刺活检对甲状腺良恶性结节的最有效的检查方法,避免了侵入性手术对患者身心的影响,同时提高了检测速度及准确率,也为甲状腺恶性肿瘤的检测提供一种新的检测手段及研究方向。
本发明中以神经酸SM(d18:2/24:1)作为甲状腺恶性肿瘤的生物标记物,其代谢组的检测通过血液就可以进行,本身是无创的,其次代谢组学可以检测到小分子代谢物,可以很好地阐述甲状腺恶性肿瘤可能发生的变化,最后通过神经酸的发现,可以很好地指导临床上对疾病的诊疗情况的掌握。
本发明适用于作为甲状腺恶性肿瘤的生物标记物。
附图说明
图1为本发明中全变量(除R3492外)建模的ROC曲线图;
图2为本发明中选择最优的ROC的模型,加入R3492后,重新做模型后建模的ROC曲线图;
图3为本发明中重新收集样本,用筛选出的变量重新做GBM模型后建模的ROC曲线图。
具体实施方式
具体实施方式一:本实施方式神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用:所述检测试剂以神经酸作为甲状腺恶性肿瘤的生物标记物。
具体实施方式二:本实施方式与具体实施方式一不同的是,所述神经酸为SM(d18:2/24:1)。其它与具体实施方式一相同。
本实施方式中神经酸SM(d18:2/24:1),属于含有神经酸链的化合物。
实验如下:
目标:应用非靶向代谢组学方案,用前瞻性研究策略,利用高分辨液相质谱技术对甲状腺乳头状癌的患者和正常人的血清进行非靶向代谢物的筛选,通过多元统计分析以及机器学习方案,确定能准确诊断和预测甲状腺癌的潜在肿瘤标志物以及预测模型,找到了以神经酸为核心的分子标记物,再进行训练集的验证,进一步说明了神经酸在疾病中的作用。
实验组:(1)所有甲状腺癌患者均经病理学诊断;(2)根据临床分期方法(TNM分期),所有患者处于早期阶段(I期);(3)所有患者未接受术前治疗,包括辅助化疗和放疗;(4)患者没有高脂血症,糖尿病和其他可能影响脂质代谢的疾病。
对照组:年龄和性别匹配的健康人,没有代谢疾病,并且通过体格检查、甲状腺超声检查及血液检查,无任何甲状腺疾病。
标本收集:实验对象超过12小时禁食,抽取实验对象5ml静脉血。收集到含有肝素作为抗凝剂的容器管中,然后离心(1500×g,15分钟)以收集血清。然后将血清转移到无菌小瓶中并立即储存在-80℃冰箱直至进一步分析(待脂质检测)。
脂质分析:采用超高效液相色谱法结合四极飞行时间串联质谱(UPLCQTOF/MS)对血清进行脂质分析。
数据分析:根据Lasso回归模型,确认交叉验证的最小平均值,并用于变量筛选。然后将筛选出的变量(除神经酸外)做GBM、RF、logistic回归、SVM模型,发现其ROC值最高的模型后,再加入神经酸变量,观察其roc的变化。
结果:
(1)根据Lasso回归模型筛选出的变量如表1所示;
表1
(2)全变量(除R3492外)建模的ROC曲线,如图1所示,发现AUC值最好的为GBM模型;
(3)选择最优的ROC的模型,加入R3492后,重新做模型,如图2所示,发现模型的AUC值由0.75上升到0.928;
(4)重新收集样本,用筛选出的变量重新做GBM模型,如图3所示,AUC值为0.917。
应用代谢组学进行脂质测定和分析,筛选生物学标志物,发现以神经酸为主的最优变量组合,再用训练集进行验证,发现以神经酸为主的最优变量组合可以指示鉴别良、恶性甲状腺结节,用于甲状腺癌的早期筛查及预后的指标;因此,以神经酸SM(d18:2/24:1)作为甲状腺恶性肿瘤的生物标记物,可以应用到制备甲状腺恶性肿瘤的检测试剂中。
首先代谢组的检测通过血液就可以进行,本身是无创的,其次代谢组学可以检测到小分子代谢物,可以很好地阐述甲状腺恶性肿瘤可能发生的变化,最后通过神经酸的发现,可以很好地指导临床上对疾病的诊疗情况的掌握。
Claims (2)
1.神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用,其特征在于所述检测试剂以神经酸作为甲状腺恶性肿瘤的生物标记物。
2.根据权利要求1所述神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用,其特征在于所述神经酸为SM(d18:2/24:1)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010819852.9A CN111999404A (zh) | 2020-08-14 | 2020-08-14 | 神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010819852.9A CN111999404A (zh) | 2020-08-14 | 2020-08-14 | 神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111999404A true CN111999404A (zh) | 2020-11-27 |
Family
ID=73472407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010819852.9A Pending CN111999404A (zh) | 2020-08-14 | 2020-08-14 | 神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111999404A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114414809A (zh) * | 2022-03-28 | 2022-04-29 | 中元伯瑞生物科技(珠海横琴)有限公司 | 用于诊断尘肺病的生物标志物的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110275065A1 (en) * | 2010-05-07 | 2011-11-10 | Ranju Ralhan | Methods and compositions for the diagnosis and treatment of thyroid cancer |
CN102483416A (zh) * | 2009-06-04 | 2012-05-30 | 梅坦诺米克斯保健有限公司 | 诊断前列腺癌的工具和方法 |
WO2013113102A1 (en) * | 2012-02-01 | 2013-08-08 | The Governors Of The University Of Alberta | USE OF PDGFR-α AS DIAGNOSTIC MARKER FOR PAPILLARY THYROID CANCER |
CN106526028A (zh) * | 2016-11-14 | 2017-03-22 | 中国药科大学 | 代谢标志物在诊断鉴别甲状腺良恶性病变中的应用 |
CN107064372A (zh) * | 2017-05-05 | 2017-08-18 | 北京骐骥生物技术有限公司 | 利用脂质生物标志物预测甲状腺癌的方法 |
CN109060977A (zh) * | 2018-07-13 | 2018-12-21 | 深圳市绘云生物科技有限公司 | 用于肝纤维化和肝硬化诊断的生物标志物和试剂盒及使用方法 |
-
2020
- 2020-08-14 CN CN202010819852.9A patent/CN111999404A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102483416A (zh) * | 2009-06-04 | 2012-05-30 | 梅坦诺米克斯保健有限公司 | 诊断前列腺癌的工具和方法 |
US20110275065A1 (en) * | 2010-05-07 | 2011-11-10 | Ranju Ralhan | Methods and compositions for the diagnosis and treatment of thyroid cancer |
WO2013113102A1 (en) * | 2012-02-01 | 2013-08-08 | The Governors Of The University Of Alberta | USE OF PDGFR-α AS DIAGNOSTIC MARKER FOR PAPILLARY THYROID CANCER |
CN106526028A (zh) * | 2016-11-14 | 2017-03-22 | 中国药科大学 | 代谢标志物在诊断鉴别甲状腺良恶性病变中的应用 |
CN107064372A (zh) * | 2017-05-05 | 2017-08-18 | 北京骐骥生物技术有限公司 | 利用脂质生物标志物预测甲状腺癌的方法 |
CN109060977A (zh) * | 2018-07-13 | 2018-12-21 | 深圳市绘云生物科技有限公司 | 用于肝纤维化和肝硬化诊断的生物标志物和试剂盒及使用方法 |
Non-Patent Citations (5)
Title |
---|
GWANG BINLEE等: "Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry", 《ANALYTICA CHIMICA ACTA》 * |
JIAN CHEN等: "Metabolite analysis-aided diagnosis of papillary thyroid cancer", 《ENDOCRINE-RELATED CANCER》 * |
SEIJI ISHIKAWA等: "Increased Expression of Phosphatidylcholine (16:0/18:1) and (16:0/18:2) in Thyroid Papillary Cancer", 《PLOS ONE》 * |
SHUAI GUO等: "Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry", 《ANALYTICAL AND BIOANALYTICAL CHEMISTRY》 * |
龚小花等: "PI3Kp85α在甲状腺乳头状癌中的表达及意义", 《温州医科大学学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114414809A (zh) * | 2022-03-28 | 2022-04-29 | 中元伯瑞生物科技(珠海横琴)有限公司 | 用于诊断尘肺病的生物标志物的应用 |
CN114414809B (zh) * | 2022-03-28 | 2022-06-21 | 中元伯瑞生物科技(珠海横琴)有限公司 | 用于诊断尘肺病的生物标志物的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110646554B (zh) | 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用 | |
Schwartz et al. | Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry | |
AU2006291988B2 (en) | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin E-related metabolites | |
CN109884300B (zh) | 结肠癌诊断标志物及其应用 | |
JP7086417B2 (ja) | 体液のリピドミクス解析に基づいて癌を診断する方法 | |
AU2012343843A1 (en) | Device and methods to diagnose pancreatic cancer | |
EP3775906B1 (en) | Metabolite-based breast cancer detection and diagnosis | |
CN112151121B (zh) | 一种食管癌诊断的诊断标志物、试剂盒及筛选方法和食管癌诊断模型的构建方法 | |
Iwano et al. | Breast cancer diagnosis based on lipid profiling by probe electrospray ionization mass spectrometry | |
CN111896641B (zh) | 结直肠癌相关雌激素血浆代谢小分子筛选方法及其应用 | |
CN117250354A (zh) | 十一种代谢标志物的检测试剂在制备乳腺癌诊断和预后产品中的应用 | |
CN111999404A (zh) | 神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用 | |
Anjo et al. | A translational view of cells' secretome analysis-from untargeted proteomics to potential circulating biomarkers | |
Park et al. | Factors associated with malignant biliary strictures in patients with atypical or suspicious cells on brush cytology | |
CN110568196B (zh) | 尿液中低级别胶质瘤相关的代谢标志物及其应用 | |
CN117368476A (zh) | 七种代谢标志物的检测试剂在制备乳腺癌诊断和预后产品中的应用 | |
WO2009061404A1 (en) | Methods for detecting or monitoring cancer using lpc as a marker | |
CN113804901B (zh) | 用于口腔鳞癌早期无创诊断的血清脂质标志物及其应用 | |
CN115762801A (zh) | 一种预测乳腺癌新辅助治疗反应的外周血脂质代谢生物标志物及应用 | |
Huang et al. | MALDI-TOF-MS analysis in the discovery and identification of the serum peptide pattern of pancreatic ductal adenocarcinoma | |
CN109444277B (zh) | 代谢标志物在制备胶质瘤诊断试剂盒方面的应用 | |
CN103175935A (zh) | 血液小分子代谢物特征图谱的制作和诊断应用 | |
CN117388495B (zh) | 用于诊断肺癌分期的代谢标志物的应用及试剂盒 | |
CN113447586B (zh) | 一种用于贲门癌筛查的标志物及检测试剂盒 | |
Giambersio et al. | Utility of detection of breast calcifications with integrated real-time radiography system (IRRS) during digital breast tomosynthesis (DBT)-guided vacuum assisted biopsy (VAB): initial single-center experience |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201127 |